PATH A
FDA-approved medicine
Two of these drugs have FDA-approved versions on the US market as of September 2026: semaglutide (the drug behind Ozempic and Wegovy) and tirzepatide (the drug behind Mounjaro and Zepbound).
As of September 2026, an approval covers one exact product, in one form, for the conditions named on its label. Form means a pen, a vial, or a tablet. The approval does not stretch to every offer that uses the same ingredient.
Source B
PATH B
Compounded medicine
Compounding means a pharmacist, a doctor, or a larger registered compounding business mixes the medicine to order, instead of supplying a finished product from a drug company. FDA calls those larger businesses outsourcing facilities.
No compounded medicine is approved as of September 2026, which means FDA has done no pre-sale check of its safety, effect, or quality.
Source C
PATH C
Research-labelled chemical
As of September 2026, a chemical sold as “research use only” is not a lawful treatment path when it is really offered for human injection.
Source D